| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Guillaume Meyer, Clara Gitahy Falcao Faria, Marine Beck, Marielle Riutort, Bruno Michel, Herv\\xc3\\xa9 Javelo. Suicidality and psychotic episodes after starting aripiprazole: two case reports. International clinical psychopharmacology. 2022-06-13. PMID:35695655. |
here, we present two major psychotic decompensations that occurred following a switch to aripiprazole in two patients with schizophrenia. |
2022-06-13 |
2023-08-14 |
Not clear |
| Jaedeok Kim, Nayoung Lee, Sang Bum Suh, Sooyeon Jang, Saeha Kim, Dong-Gyu Kim, Jong Kook Park, Keun-Wook Lee, Soo Young Choi, Chan Hee Le. Metformin ameliorates olanzapine-induced disturbances in POMC neuron number, axonal projection, and hypothalamic leptin resistance. BMB reports. 2022-06-02. PMID:35651327. |
while atypical antipsychotics such as aripiprazole are not associated with obesity and diabetes, olanzapine is still widely used based on the anticipation that it is more effective in treating severe schizophrenia than aripiprazole, despite its metabolic side effects. |
2022-06-02 |
2023-08-13 |
mouse |
| Pierre-Michel Llorca, Philippe Nuss, \\xc3\\x89ric Fakra, Isabelle Alamome, Dominique Drapier, Wissam El Hage, Renaud Jardri, St\\xc3\\xa9phane Mouchabac, Marc Rabbani, Nicolas Simon, Marie-No\\xc3\\xablle Vacheron, Jean-Michel Azori. Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study. BMC psychiatry. vol 22. issue 1. 2022-06-01. PMID:35643542. |
place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a delphi consensus study. |
2022-06-01 |
2023-08-13 |
Not clear |
| Pierre-Michel Llorca, Philippe Nuss, \\xc3\\x89ric Fakra, Isabelle Alamome, Dominique Drapier, Wissam El Hage, Renaud Jardri, St\\xc3\\xa9phane Mouchabac, Marc Rabbani, Nicolas Simon, Marie-No\\xc3\\xablle Vacheron, Jean-Michel Azori. Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study. BMC psychiatry. vol 22. issue 1. 2022-06-01. PMID:35643542. |
aripiprazole is a second-generation antipsychotic, efficacious in patients with schizophrenia during acute episodes. |
2022-06-01 |
2023-08-13 |
Not clear |
| Jaros\\xc5\\x82aw Sobi\\xc5\\x9b, \\xc5\\x81ukasz Kunert, Monika Rykaczewska-Czerwi\\xc5\\x84ska, El\\xc5\\xbcbieta \\xc5\\x9awi\\xc4\\x99tochowska, Piotr Gorczyc. The effect of aripiprazole on leptin levels of patients with chronic schizophrenia and a comparison of leptin, acute phase protein, and cytokine levels with regard to body mass and body composition indexes. Endokrynologia Polska. vol 73. issue 1. 2022-04-05. PMID:35381103. |
the effect of aripiprazole on leptin levels of patients with chronic schizophrenia and a comparison of leptin, acute phase protein, and cytokine levels with regard to body mass and body composition indexes. |
2022-04-05 |
2023-08-13 |
Not clear |
| Jaros\\xc5\\x82aw Sobi\\xc5\\x9b, \\xc5\\x81ukasz Kunert, Monika Rykaczewska-Czerwi\\xc5\\x84ska, El\\xc5\\xbcbieta \\xc5\\x9awi\\xc4\\x99tochowska, Piotr Gorczyc. The effect of aripiprazole on leptin levels of patients with chronic schizophrenia and a comparison of leptin, acute phase protein, and cytokine levels with regard to body mass and body composition indexes. Endokrynologia Polska. vol 73. issue 1. 2022-04-05. PMID:35381103. |
the aim of this study was to test the effect of aripiprazole on leptin, insulin, acute phase proteins, and selected cytokines levels in patients with chronic schizophrenia. |
2022-04-05 |
2023-08-13 |
Not clear |
| Mette \\xc3\\x98degaard Nielsen, Tina Dam Kristensen, Kirsten Borup Bojesen, Birte Y Glenth\\xc3\\xb8j, Cecilie K Lemvigh, Bj\\xc3\\xb8rn H Ebdru. Differential Effects of Aripiprazole and Amisulpride on Negative and Cognitive Symptoms in Patients With First-Episode Psychoses. Frontiers in psychiatry. vol 13. 2022-04-04. PMID:35370857. |
aripiprazole is hypothesized to have an effect on negative and cognitive symptoms in schizophrenia. |
2022-04-04 |
2023-08-13 |
Not clear |
| Zofia Rog\\xc3\\xb3\\xc5\\xbc, Kinga Kami\\xc5\\x84ska, Marta Anna Lech, El\\xc5\\xbcbieta Lorenc-Koc. N-Acetylcysteine and Aripiprazole Improve Social Behavior and Cognition and Modulate Brain BDNF Levels in a Rat Model of Schizophrenia. International journal of molecular sciences. vol 23. issue 4. 2022-02-26. PMID:35216241. |
n-acetylcysteine and aripiprazole improve social behavior and cognition and modulate brain bdnf levels in a rat model of schizophrenia. |
2022-02-26 |
2023-08-13 |
rat |
| Blanca Fern\\xc3\\xa1ndez-Abascal, Maria Recio-Barbero, Margarita S\\xc3\\xa1enz-Herrero, Rafael Segarr. Long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report. Therapeutic advances in psychopharmacology. vol 11. 2022-02-21. PMID:35186259. |
long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report. |
2022-02-21 |
2023-08-13 |
Not clear |
| Virginio Salvi, Cristina Appignanesi, Brodinela Marpepa, Laura Orsolini, Umberto Volp. Aripiprazole LAI two-injection start in a 16 year-old adolescent with schizophrenia. Neuropsychopharmacology reports. 2022-02-19. PMID:35182040. |
aripiprazole lai two-injection start in a 16 year-old adolescent with schizophrenia. |
2022-02-19 |
2023-08-13 |
Not clear |
| Virginio Salvi, Cristina Appignanesi, Brodinela Marpepa, Laura Orsolini, Umberto Volp. Aripiprazole LAI two-injection start in a 16 year-old adolescent with schizophrenia. Neuropsychopharmacology reports. 2022-02-19. PMID:35182040. |
aripiprazole long-acting injection (lai) is approved for the treatment of schizophrenia in adults. |
2022-02-19 |
2023-08-13 |
Not clear |
| Virginio Salvi, Cristina Appignanesi, Brodinela Marpepa, Laura Orsolini, Umberto Volp. Aripiprazole LAI two-injection start in a 16 year-old adolescent with schizophrenia. Neuropsychopharmacology reports. 2022-02-19. PMID:35182040. |
aripiprazole showed efficacy in the treatment of adolescents with acute schizophrenia in several controlled trials, leading to its approval for 13- to 17-year-old adolescents with schizophrenia by the ema. |
2022-02-19 |
2023-08-13 |
Not clear |
| N V Baymeeva, I I Miroshnichenko, A I Platova, D V Tikhonov, V G Kaled. [Therapeutic drug monitoring of aripiprazole as part of the individualization of the pharmacotherapy of schizophrenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 122. issue 1. 2022-02-17. PMID:35175709. |
[therapeutic drug monitoring of aripiprazole as part of the individualization of the pharmacotherapy of schizophrenia]. |
2022-02-17 |
2023-08-13 |
Not clear |
| N V Baymeeva, I I Miroshnichenko, A I Platova, D V Tikhonov, V G Kaled. [Therapeutic drug monitoring of aripiprazole as part of the individualization of the pharmacotherapy of schizophrenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 122. issue 1. 2022-02-17. PMID:35175709. |
to personalize pharmacotherapy with aripiprazole in patients with schizophrenia via therapeutic drug monitoring (tdm). |
2022-02-17 |
2023-08-13 |
Not clear |
| Pavel Mohr, Jir\\xc3\\xad Masopust, Miloslav Kope\\xc4\\x8de. Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy? Frontiers in psychiatry. vol 12. 2022-02-11. PMID:35145438. |
in two acute schizophrenia rcts of cariprazine and brexpiprazole, aripiprazole was used as an indirect comparator to control for study sensitivity. |
2022-02-11 |
2023-08-13 |
Not clear |
| Geoffrey Russell, Samuel Reinfeld, Olivia Kam, Gloria Lee, Melissa Weiss, Maju Mathew Kool. Case series on aripiprazole and dopamine supersensitivity psychosis. International clinical psychopharmacology. 2022-02-10. PMID:35143441. |
diagnosis of schizophrenia experienced severe worsening of psychosis within 4-5 days of abrupt switching to aripiprazole from a full d2 antagonist. |
2022-02-10 |
2023-08-13 |
Not clear |
| Zhe Lu, Yuyanan Zhang, Hao Yan, Yi Su, Liangkun Guo, Yundan Liao, Tianlan Lu, Hao Yu, Lifang Wang, Jun Li, Wenqiang Li, Yongfeng Yang, Xiao Xiao, Luxian Lv, Yunlong Tan, Dai Zhang, Weihua Yu. ATAD3B and SKIL polymorphisms associated with antipsychotic-induced QTc interval change in patients with schizophrenia: a genome-wide association study. Translational psychiatry. vol 12. issue 1. 2022-02-09. PMID:35136033. |
a total of 2040 patients with schizophrenia were randomly assigned to six groups (olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, and first-generation antipsychotics; first-generation antipsychotics including haloperidol or perphenazine were also assigned randomly) and received 6-week antipsychotic treatment. |
2022-02-09 |
2023-08-13 |
Not clear |
| Chia-Hao Ma, Hung-Yu Chan, Ming H Hsieh, Chen-Chung Liu, Chih-Min Liu, Hai-Gwo Hwu, Ching-Hua Kuo, Wei J Chen, Tzung-Jeng Hwan. Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia. Therapeutic advances in psychopharmacology. vol 12. 2022-02-03. PMID:35111295. |
identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia. |
2022-02-03 |
2023-08-13 |
Not clear |
| Renata Cristina Mendes Ferreira, Douglas Lamounier de Almeida, Igor Dimitri Gama Duarte, Daniele Cristina Aguiar, Fabr\\xc3\\xadcio Ara\\xc3\\xbajo Moreira, Thiago Roberto Lima Romer. The antipsychotic aripiprazole induces peripheral antinociceptive effects through PI3K\\xce\\xb3/NO/cGMP/K European journal of pain (London, England). 2022-01-19. PMID:35044019. |
the antipsychotic aripiprazole induces peripheral antinociceptive effects through pi3k\xce\xb3/no/cgmp/k aripiprazole is an antipsychotic drug used to treat schizophrenia and bipolar disorder. |
2022-01-19 |
2023-08-13 |
Not clear |
| Adam Wichniak, Jerzy Samochowiec, Agata Szulc, Dominika Dudek, Janusz Heitzman, Ma\\xc5\\x82gorzata Janas-Kozik, Tomasz Wola\\xc5\\x84czyk, Joanna Rymaszewska, Marcin Siwek, Przemys\\xc5\\x82aw Bie\\xc5\\x84kowsk. The position statement of the Working Group of the Polish Psychiatric Association on the use of D2/D3 dopamine receptor partial agonists in the treatment of mental disorders. Psychiatria polska. vol 55. issue 5. 2022-01-08. PMID:34997736. |
this is the reason for the increasing use of these drugs in the treatment of schizophrenia and mood disorders, and in the case of aripiprazole also in obsessive-compulsive, autism-spectrum and tic disorders. |
2022-01-08 |
2023-08-13 |
Not clear |